#BEGIN_DRUGCARD DB01879

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C32H26N2O10S2

# Chemical_IUPAC_Name:
(2R)-2-{N-methyl-1-[2-(naphthalene-2-sulfonamido)-5-[(naphthalene-2-sulfonyl)oxy]phenyl]formamido}butanedioic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
(S)-2-{Methyl-[2-(Naphthalene-2-Sulfonylamino)-5-(Naphthalene-2-Sulfonyloxy)-Benzoyl]-Amino}-Succinicacid

# HET_ID:
TAV

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C32H26N2O10S2/c1-34(29(32(38)39)19-30(35)36)31(37)27-18-24(44-46(42,43)26-14-11-21-7-3-5-9-23(21)17-26)12-15-28(27)33-45(40,41)25-13-10-20-6-2-4-8-22(20)16-25/h2-18,29,33H,19H2,1H3,(H,35,36)(H,38,39)/t29-/m1/s1

# InChI_Key:
InChIKey=JOAALZBSMWLOPQ-GDLZYMKVSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1879

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
662.686

# Molecular_Weight_Mono:
662.102886442

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1YBG

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
3.6

# Predicted_LogS:
-6.2

# Predicted_Water_Solubility:
4.44e-04 g/l

# Primary_Accession_No:
DB01879

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936247

# PubChem_Substance_ID:
46504961

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03011

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN([C@H](CC(O)=O)C(O)=O)C(=O)C1=CC(OS(=O)(=O)C2=CC=C3C=CC=CC3=C2)=CC=C1NS(=O)(=O)C1=CC=C2C=CC=CC2=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:34 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Z11835

# Drug_Target_1_GenBank_ID_Protein:
41344

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
murA

# Drug_Target_1_Gene_Sequence:
>1260 bp
ATGGATAAATTTCGTGTACAGGGGCCGACGCGCCTCCAGGGCGAAGTCACAATTTCTGGC
GCGAAAAACGCCGCGCTGCCGATCCTCTTTGCTGCGCTGCTCGCGGAAGAGCCGGTAGAA
ATTCAGAACGTACCGAAGCTGAAAGATATCGACACCACCATGAAGCTGCTCACCCAGTTG
GGGACGAAAGTCGAGCGTAATGGCTCCGTCTGGATCGATGCCAGCAACGTGAACAACTTC
TCAGCACCGTACGACCTGGTGAAAACCATGCGTGCATCCATCTGGGCGCTTGGCCCGCTG
GTAGCGCGTTTTGGTCAGGGACAGGTGTCACTGCCTGGTGGTTGCGCCATTGGCGCGCGT
CCTGTTGACCTGCATATCTTCGGTCTGGAGAAGCTGGGCGCGGAGATCAAACTGGAAGAA
GGTTACGTTAAAGCGTCCGTTAATGGCCGCCTGAAAGGCGCACACATTGTCATGGATAAA
GTGAGCGTTGGCGCAACCGTCACCATTATGTCCGCGGCAACGCTGGCAGAAGGTACCACC
ATTATCGAAAACGCCGCGCGCGAGCCGGAAATTGTGGATACTGCCAACTTCCTCGTGGCG
CTGGGTGCAAAAATCTCTGGCCAGGGTACCGATCGCATCACCATTGAAGGCGTTGAGCGT
CTGGGGGGCGGTGTGTATCGCGTTCTGCCAGACCGTATTGAAACCGGGACTTTCCTGGTG
GCTGCGGCCATTTCTGGCGGCAAGATTGTTTGCCGTAATGCGCAGCCTGACACCCTGGAT
GCGGTGCTGGCGAAGCTGCGTGAAGCGGGTGCGGATATCGAAACCGGTGAAGACTGGATC
AGCCTTGATATGCACGGTAAACGTCCAAAAGCGGTAACCGTTCGCACGGCGCCGCATCCG
GCATTCCCGACCGATATGCAGGCTCAGTTCACGCTGCTGAACCTGGTGGCAGAAGGTACC
GGTGTGATCACCGAGACTATCTTCGAGAACCGCTTCATGCACGTACCGGAGCTGATCCGT
ATGGGCGCACATGCAGAGATCGAAAGTAACACGGTGATTTGCCACGGTGTTGAGAAGCTC
TCCGGTGCGCAGGTTATGGCAACCGATCTGCGTGCGTCTGCGAGCCTGGTATTAGCGGGT
TGTATCGCGGAAGGAACGACGGTTGTGGATCGTATCTACCACATCGATCGTGGTTACGAG
CGTATTGAAGACAAACTGCGCGCGCTGGGTGCCAATATCGAGCGTGTGAAGGGCGAGTAA

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
10694381	Schonbrunn E, Eschenburg S, Krekel F, Luger K, Amrhein N: Role of the loop containing residue 115 in the induced-fit mechanism of the bacterial cell wall biosynthetic enzyme MurA. Biochemistry. 2000 Mar 7;39(9):2164-73.
1577165	Wanke C, Falchetto R, Amrhein N: The UDP-N-acetylglucosamine 1-carboxyvinyl-transferase of Enterobacter cloacae. Molecular cloning, sequencing of the gene and overexpression of the enzyme. FEBS Lett. 1992 Apr 27;301(3):271-6.
8805592	Schonbrunn E, Sack S, Eschenburg S, Perrakis A, Krekel F, Amrhein N, Mandelkow E: Crystal structure of UDP-N-acetylglucosamine enolpyruvyltransferase, the target of the antibiotic fosfomycin. Structure. 1996 Sep 15;4(9):1065-75.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2367

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
44777

# Drug_Target_1_Name:
UDP-N-acetylglucosamine 1-carboxyvinyltransferase

# Drug_Target_1_Number_of_Residues:
419

# Drug_Target_1_PDB_ID:
1NAW

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00275	EPSP_synthase

# Drug_Target_1_Protein_Sequence:
>UDP-N-acetylglucosamine 1-carboxyvinyltransferase
MDKFRVQGPTRLQGEVTISGAKNAALPILFAALLAEEPVEIQNVPKLKDIDTTMKLLTQL
GTKVERNGSVWIDASNVNNFSAPYDLVKTMRASIWALGPLVARFGQGQVSLPGGCAIGAR
PVDLHIFGLEKLGAEIKLEEGYVKASVNGRLKGAHIVMDKVSVGATVTIMSAATLAEGTT
IIENAAREPEIVDTANFLVALGAKISGQGTDRITIEGVERLGGGVYRVLPDRIETGTFLV
AAAISGGKIVCRNAQPDTLDAVLAKLREAGADIETGEDWISLDMHGKRPKAVTVRTAPHP
AFPTDMQAQFTLLNLVAEGTGVITETIFENRFMHVPELIRMGAHAEIESNTVICHGVEKL
SGAQVMATDLRASASLVLAGCIAEGTTVVDRIYHIDRGYERIEDKLRALGANIERVKGE

# Drug_Target_1_Reaction:
phosphoenolpyruvate + UDP-N-acetyl-D-glucosamine = phosphate + UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Cell wall formation. Adds enolpyruvyl to UDP-N- acetylglucosamine. Target for the antibiotic phosphomycin

# Drug_Target_1_SwissProt_ID:
P33038

# Drug_Target_1_SwissProt_Name:
MURA_ENTCC

# Drug_Target_1_Synonyms:
EC 2.5.1.7
EPT
Enoylpyruvate transferase
UDP-N-acetylglucosamine enolpyruvyl transferase

# Drug_Target_1_Theoretical_pI:
5.92

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01879
